Posts by Nicholas Dyson, PhD
-
Olaparib/Temozolomide Promising for Relapsed Small-Cell Lung Cancer
Benjamin J. Drapkin, MD, PhD, Anna Farago, MD, PhD, and Nicholas J. Dyson, PhD, of the Cancer Center demonstrated that the combination of olaparib, an inhibitor of DNA-damage repair, and temozolomide is highly active against relapsed SCLC—and they've identified genes that seem to predict response to the regimen.
